| Donor information | Experiments | Number | Gender, age | Level pathology, grade | Sublethal oxidative stress | Lethal oxidative stress |
| 1 | M, 35 | L4/L5 Herniation IV | H2O2 sensitivity study, p21 time course Senescence validation 10 days: additive effect | H2O2 sensitivity study PI/A | 2 | F, 77 | L4/L5 DDD III | p21 time course 10 days: additive effect | JC-1, MTT | 3 | F, 53 | L4/L5 DDD IV | H2O2 sensitivity study, p21 time course Senescence validation 10 days: additive effect | H2O2 sensitivity study PI/A, MTT | 4 | F, 39 | L5/S1 Herniation V | H2O2 sensitivity study Senescence validation 10 days: antioxidant | H2O2 sensitivity study PI/A, MTT | 5 | F, 31 | L4/L5 Herniation uk | H2O2 sensitivity study Senescence validation | H2O2 sensitivity study JC-1, PI/A, MTT | 6 | F, 64 | L4/L5 DDD III | H2O2 sensitivity study Senescence validation | H2O2 sensitivity study JC-1, PI/A, MTT | 7 | F, 53 | L5/S1 Herniation IV | — | JC-1 | 8 | M, 50 | L4/5 DDD III | — | JC-1 | 9 | F, 54 | L5/S1 Herniation V | 10 days: recovery, RT qPCR | — | 10 | M, 64 | L5/S1 Herniation III | 10 days: recovery, RT qPCR | — | 11 | M, 44 | L5/S1 Her IV | 10 days: antioxidant, RT qPCR | — | 12 | M, 56 | L4/L5 Herniation III | 10 days: recovery, RT qPCR | — | 13 | F, 51 | C4/5 Herniation III | 10 days: antioxidant | — | 14 | F, 42 | L3/L4 Herniation III | 10 days: antioxidant | — | 15 | F, 35 | L5/S1 DDD, Herniation IV | 10 days: recovery | — | 16 | M, 41 | L4/L5 DDD III | 10 days: additive effect | — | 17 | M, 40 | L5/S2 DDD, Herniation V | 10 days: antioxidant | — | 18 | M, 50 | L4/L5 DDD, Herniation III | 10 days: additive effect | — | 19 | F, 42 | L3/L4 Herniation III | 10 days: recovery | — | 20 | M, 43 | L5/S1 DDD, uk | — | JC-1, bright field, MTT, MTT (I) | 21 | F, 51 | L4/L5 DDD IV | — | JC-1, bright field, MTT, MTT (LY), MTT (I) | 22 | M, 47 | L4/L5 DDD, Herniation III | — | JC-1, bright field, MTT | 23 | F, 44 | L4/L5 DDD III | — | JC-1, bright field, MTT, MTT (LY), MTT (I) | 24 | F, 43 | L5/S1 DDD, Herniation III | — | JC-1, bright field, MTT, MTT (LY), MTT (I) | 25 | M, 47 | L4/5 DDD, Herniation III | — | Lethal: MTT (LY), MTT (I) | 26 | M, 39 | L4/5 DDD, Herniation IV | — | Lethal: MTT (LY), MTT (I) | 27 | M, 21 | L5/S1 Herniation III | — | Lethal: MTT (LY), MTT (I) | 28 | F, 43 | L4/5 DDD, Herniation IV | — | Lethal: MTT (LY), MTT (I) | 29 | M, 33 | L5/S1 Herniation III | — | Lethal: WB | 30 | F, 39 | L5/S1 DDD, Herniation III | — | Lethal: MTT (LY), WB, MTT (I) | 31 | F, 39 | L4/5 DDD, Herniation IV | — | Lethal: MTT (LY), WB, MTT (I) | 32 | uk | uk | — | Lethal: MTT (LY), WB | 33 | M, 55 | L3/4 DDD III | — | Lethal: WB | 34 | F, 56 | L3/4 Herniation IV | — | Lethal: MTT (LY), WB | 35 | M, uk | L4/5 Herniation uk | — | Lethal: MTT (LY) | 36 | uk | uk | — | Lethal: MTT (LY) |
|
|